Alnylam Pharmaceuticals (ALNY) Share-based Compensation Growth (1y) (2010 - 2026)
Alnylam Pharmaceuticals (ALNY) Share-based Compensation Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 71.86% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -3.46% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -8.89% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,486.54% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -22.43% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -4.01% |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -22.43% |
| Mar 31, 2026 | 23.70% |
| Dec 31, 2025 | 141.86% |
| Sep 30, 2025 | 485.25% |
| Jun 30, 2025 | -100.96% |
| Mar 31, 2025 | 1,169.51% |
| Dec 31, 2024 | -507.51% |
| Sep 30, 2024 | -28.36% |
| Jun 30, 2024 | 76.59% |
| Mar 31, 2024 | -98.06% |
| Dec 31, 2023 | -1.81% |
| Sep 30, 2023 | -50.10% |
| Jun 30, 2023 | 148.77% |
| Mar 31, 2023 | 36.37% |
| Dec 31, 2022 | -4.07% |
| Sep 30, 2022 | 283.97% |
| Jun 30, 2022 | -5.01% |
| Mar 31, 2022 | -47.40% |
| Dec 31, 2021 | 30.07% |
| Sep 30, 2021 | -63.14% |